Emanuelle Araujo Lima Bellaguarda

  • 216 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Inflammatory bowel disease (Crohn's disease and ulcerative colitis), therapeutic drug monitoring, clinical trials

Training Experience

2011Residency, Boston University Medical Center
2014Fellowship, University of Chicago
2015Fellowship, Northwestern University, Feinberg School of Medicine

Education/Academic qualification

MD, Federal University of Ceara

… → 2006

Research interests

  • Inflammatory Bowel Disease

Fingerprint Dive into the research topics where Emanuelle Araujo Lima Bellaguarda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

  • 216 Citations
  • 10 Article
  • 2 Review article
  • 1 Letter

Checkpoint Inhibitor-Induced Colitis

Bellaguarda, E. & Hanauer, S., Feb 1 2020, In : The American journal of gastroenterology. 115, 2, p. 202-210 9 p.

Research output: Contribution to journalArticle

Open Access
  • Disordered Eating, Body Dissatisfaction, and Psychological Distress in Patients with Inflammatory Bowel Disease (IBD)

    Wabich, J., Bellaguarda, E., Joyce, C., Keefer, L. & Kinsinger, S., Jun 1 2020, In : Journal of Clinical Psychology in Medical Settings. 27, 2, p. 310-317 8 p.

    Research output: Contribution to journalArticle

  • Recurrent brisk haematochezia in a patient with quiescent Crohn's disease

    Gasanova, Z., Lemmer, A. & Bellaguarda, E., Jan 1 2020, (Accepted/In press) In : Frontline Gastroenterology. flgastro-2019-101404.

    Research output: Contribution to journalArticle

    Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis

    Limketkai, B. N., Shah, S. C., Hirano, I., Bellaguarda, E. & Colombel, J. F., Dec 1 2019, In : Gut. 68, 12, p. 2152-2160 9 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

    Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., Singh, S., Pekow, J. & Rubin, D. T., Mar 2018, In : Alimentary Pharmacology and Therapeutics. 47, 6, p. 753-762 10 p.

    Research output: Contribution to journalArticle

  • 28 Scopus citations